12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ARN-810: Phase I started

Aragon began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral ARN-810 daily in about 72 postmenopausal women. Patients will receive...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >